TROP-2 serves as a prognostic factor and marker for various cancers, showing overexpression in solid tumour cancers like breast, cervix, colorectal, oesophagus, gastric, lung, oral cavity squamous cell carcinoma, ovary, pancreas, prostate, stomach, thyroid, urinary bladder, and uterus. Here, TACSTD2 is linked to cancer.